Uk medicines and healthcare products regulatory agency confirms acceptance of marketing authorization application for proposed biosimilar to xolair® (omalizumab)

Reykjavik, iceland, piscataway, n.j. and london, march 26, 2025 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, kashiv biosciences llc (“kashiv”), a fully integrated biopharmaceutical company headquartered in new jersey, us, and advanz pharma, a uk-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the uk medicines and healthcare products regulatory agency (mhra) has accepted a marketing application for avt23, a proposed biosimilar to xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. global sales of xolair in 2024 were about usd $4.4 billion [1].
ALVO Ratings Summary
ALVO Quant Ranking